tbuckley/cabot-search huggingface dataset:
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Authors: Dongdong Xia, Wei Bai, Enxin Wang, Jiaping Li, Xiaoming Chen, Zhexuan Wang, Mingsheng Huang, Ming Huang, Junhui Sun, Weizhu Yang, Zhengyu Lin, Jianbing Wu, Zixiang Li, Shufa Yang, Xu Zhu, Zaizhong Chen, Yanfang Zhang, Wenzhe Fan, Qicong Mai, Rong Ding, Chunhui Nie, Long Feng, Xueda Li, Wukui Huang, Jun Sun, Qiuhe Wang, Yong Lv, Xiaomei Li, Bohan Luo, Zhengyu Wang, Jie Yuan, Wengang Guo, Kai Li, Bing Li, Ruijun Li, Zhanxin Yin, Jielai Xia, Guohong Han
Journal: Liver Cancer (2022)

Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice.This retrospective analysis included 142 consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who received lenvatinib alone as first-line treatment from 15 Chinese academic centers from November 2018 to November 2019. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) were evaluated by modified Response Evaluation Criteria in Solid Tumors criteria, and safety profiles were compared between the two groups.The median OS and PFS were significantly longer in the combined therapy group than in the monotherapy group in whole cohort (median OS, 15.9 vs. 8.6 months, p = 0.0022; median PFS, 8.6 vs. 4.4 months, p < 0.001) and after propensity score matching analysis (median OS, 13.8 vs. 7.8 months, p = 0.03; median PFS, 7.8 vs. 4.5 months, p = 0.009). Moreover, the treatment option was an independent prognostic factor for OS and PFS with adjustment based upon baseline characteristics (adjusted hazard ratio [HR]: 0.53, 95% confidence interval [CI]: 0.36-0.78, p = 0.001, and adjusted HR: 0.42, 95% CI: 0.30-0.60, p < 0.001, respectively) and propensity score (adjusted HR: 0.52, 95% CI: 0.36-0.76, p = 0.001, and adjusted HR: 0.46, 95% CI: 0.33-0.64, p < 0.001, respectively). Moreover, a greater ORR was observed in the combined group (ORR: 46.48% vs. 13.05%, p < 0.001). Furthermore, the most common adverse events (AEs) were elevated aspartate aminotransferase (54.9%) and fatigue (46.4%) in the lenvatinib plus DEB-TACE group and lenvatinib group, respectively. Most AEs were mild-to-moderate and manageable.With well-tolerated safety, lenvatinib plus DEB-TACE was more effective than lenvatinib monotherapy in improving OS, PFS, and ORR. Thus, it may be a promising treatment for advanced HCC. Future prospective studies confirming these findings are warranted.
EMERGENT PERCUTANEOUS RIGHT TRANS-AXILLARY TAVR; A SAFE ALTERNATIVE TO UNFAVORABLE TRANSFEMORAL APPROACH.
Authors: Mohamed Elrifai, Logan Reimer, Akhil Rasim Reddy, Manaquibb Khan, Derar Albashaireh, Bhavith Aruni
Journal: Journal of the American College of Cardiology (2022)
BPI22-018: Experience of Patients With Smoldering Systemic Mastocytosis Treated With Avapritinib as Part of a Global Compassionate Use Program
Authors: Gerard Thomas Hoehn, Bethany Bearden, Sona Doshi, Kjersten Teeter
Journal: Journal of the National Comprehensive Cancer Network (2022)

"BPI22-018: Experience of Patients With Smoldering Systemic Mastocytosis Treated With Avapritinib as Part of a Global Compassionate Use Program" published on 31 Mar 2022 by National Comprehensive Cancer Network.
A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis
Authors: Chiara Colombo, Marco Fiore, Giovanni Grignani, Francesco Tolomeo, Alessandra Merlini, Elena Palassini, Paola Collini, Silvia Stacchiotti, Paolo Giovanni Casali, Federica Perrone, Luigi Mariani, Alessandro Gronchi
Journal: Clinical Cancer Research (2022)

Abstract Purpose: To prospectively assess the behavior of primary sporadic (not familial adenomatous polyposis–associated) desmoid fibromatosis (DF) managed by active surveillance (AS). Experimental Design: This is an Italian prospective, multicenter, observational study (NCT 02547831) including patients ≥16 years with primary sporadic DF at any site. Patients were assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Primary endpoint was progression-free survival (PFS) at 3 years. Treatment-free survival (TFS) was also analyzed. PFS and TFS were calculated by Kaplan–Meier plots and compared by log-rank test. Cox proportional hazard multivariable regression analyses were performed. Results: From 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm. CTNNB1 mutations were T41A (50%), S45F (12%), other (19%), wild-type (19%). At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%–66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%–75.9%). Larger tumor size and extremity location were associated to shorter TFS and a trend for S45F mutation was also observed (P = 0.06), while none of the mentioned variables was significantly associated with PFS. Conclusions: In primary DF, AS can be proposed, because disease stabilization and spontaneous regression frequently occur. However, extra care should be taken for patients with tumors of larger size, extremity location, and S45F mutation. See related commentary by Greene and Van Tine, p. 3911
ADDITIVE VALUE OF CARDIAC MAGNETIC RESONANCE IMAGING TO CONVENTIONAL SURGICAL RISK SCORES IN AORTIC VALVE SURGERY
Authors: Meghana Patil, Tom Kai Ming Wang, Felix Berglund, Pooja Podugu, Saeid Mirzai, Hussein Awwad, Lars G. Svensson, Brian P. Griffin, Scott D. Flamm, Wai Hong Wilson Tang, Deborah Kwon
Journal: Journal of the American College of Cardiology (2022)
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis
Authors: Davies Adeloye, Peige Song, Yajie Zhu, Harry Campbell, Aziz Sheikh, Igor Rudan
Journal: The Lancet Respiratory Medicine (2022)

Chronic obstructive pulmonary disease (COPD) is an increasingly important cause of morbidity, disability, and mortality worldwide. We aimed to estimate global, regional, and national COPD prevalence and risk factors to guide policy and population interventions.For this systematic review and modelling study, we searched MEDLINE, Embase, Global Health, and CINAHL, for population-based studies on COPD prevalence published between Jan 1, 1990, and Dec 31, 2019. We included data reported using the two main case definitions: the Global Initiative for Chronic Obstructive Lung Disease fixed ratio (GOLD; FEV1/FVC<0·7) and the lower limit of normal (LLN; FEV1/FVC<LLN). We employed a multilevel multivariable mixed-effects meta-regression approach to generate the age-specific and sex-specific prevalence of COPD in 2019 for high-income countries (HICs) and low-income and middle-income countries (LMICs) according to the World Bank definition. Common risk factors for GOLD-COPD were evaluated using a random-effects meta-analysis.We identified 162 articles reporting population-based studies conducted across 260 sites in 65 countries. In 2019, the global prevalence of COPD among people aged 30-79 years was 10·3% (95% CI 8·2-12·8) using the GOLD case definition, which translates to 391·9 million people (95% CI 312·6-487·9), and 7·6% (5·8-10·1) using the LLN definition, which translates to 292·0 million people (219·8-385·6). Using the GOLD definition, we estimated that 391·9 million (95% CI 312·6-487·9) people aged 30-79 years had COPD worldwide in 2019, with most (315·5 million [246·7-399·6]; 80·5%) living in LMICs. The overall prevalence of GOLD-COPD among people aged 30-79 years was the highest in the Western Pacific region (11·7% [95% CI 9·3-14·6]) and lowest in the region of the Americas (6·8% [95% CI 5·6-8·2]). Globally, male sex (OR 2·1 [95% CI 1·8-2·3]), smoking (current smoker 3·2 [2·5-4·0]; ever smoker 2·3 [2·0-2·5]), body-mass index of less than 18·5 kg/m2 (2·2 [1·7-2·7]), biomass exposure (1·4 [1·2-1·7]), and occupational exposure to dust or smoke (1·4 [1·3-1·6]) were all substantial risk factors for COPD.With more than three-quarters of global COPD cases in LMICs, tackling this chronic condition is a major and increasing challenge for health systems in these settings. In the absence of targeted population-wide efforts and health system reforms in these settings, many of which are under-resourced, achieving a substantial reduction in the burden of COPD globally might remain a difficult task.National Institute for Health Research and Health Data Research UK.
Exposure to Outdoor Particulate Matter Air Pollution and Risk of Gastrointestinal Cancers in Adults: A Systematic Review and Meta-Analysis of Epidemiologic Evidence
Authors: Natalie Pritchett, Emily C. Spangler, George M. Gray, Alicia A. Livinski, Joshua N. Sampson, Sanford M. Dawsey, Rena R. Jones
Journal: Environmental Health Perspectives (2022)

Outdoor air pollution is a known lung carcinogen, but research investigating the association between particulate matter (PM) and gastrointestinal (GI) cancers is limited.We sought to review the epidemiologic literature on outdoor PM and GI cancers and to put the body of studies into context regarding potential for bias and overall strength of evidence.We conducted a systematic review and meta-analysis of epidemiologic studies that evaluated the association of fine PM [PM with an aerodynamic diameter of ≤2.5μm (PM2.5)] and PM10 (aerodynamic diameter ≤10μm) with GI cancer incidence or mortality in adults. We searched five databases for original research published from 1980 to 2021 in English and summarized findings for studies employing a quantitative estimate of exposure overall and by specific GI cancer subtypes. We evaluated the risk of bias of individual studies and the overall quality and strength of the evidence according to the Navigation Guide methodology, which is tailored for environmental health research.Twenty studies met inclusion criteria and included participants from 14 countries; nearly all were of cohort design. All studies identified positive associations between PM exposure and risk of at least one GI cancer, although in 3 studies these relationships were not statistically significant. Three of 5 studies estimated associations with PM10 and satisfied inclusion criteria for meta-analysis, but each assessed a different GI cancer and were therefore excluded. In the random-effects meta-analysis of 13 studies, PM2.5 exposure was associated with an increased risk of GI cancer overall [risk ratio (RR)=1.12; 95% CI: 1.01, 1.24]. The most robust associations were observed for liver cancer (RR=1.31; 95% CI: 1.07, 1.56) and colorectal cancer (RR=1.35; 95% CI: 1.08, 1.62), for which all studies identified an increased risk. We rated most studies with "probably low" risk of bias and the overall body of evidence as "moderate" quality with "limited" evidence for this association. We based this determination on the generally positive, but inconsistently statistically significant, effect estimates reported across a small number of studies.We concluded there is some evidence of associations between PM2.5 and GI cancers, with the strongest evidence for liver and colorectal cancers. Although there is biologic plausibility for these relationships, studies of any one cancer site were few and there remain only a small number overall. Studies in geographic areas with high GI cancer burden, evaluation of the impact of different PM exposure assessment approaches on observed associations, and investigation of cancer subtypes and specific chemical components of PM are important areas of interest for future research. https://doi.org/10.1289/EHP9620.
DIAGNOSTIC PERFORMANCE OF CORONARY ANGIOGRAPHY- AND INTRAVASCULAR IMAGINGBASED FRACTIONAL FLOW RESERVE TO DETECT FUNCTIONALLY SIGNIFICANT CORONARY STENOSES: A SYSTEMIC REVIEW AND META-ANALYSIS
Authors: Tatsunori Takahashi, Doosup Shin, Toshiki Kuno, Joo Myung Lee, Azeem Latib, William Fuller Fearon, Akiko Maehara, Yuhei Kobayashi
Journal: Journal of the American College of Cardiology (2022)
Abstract P1-13-07: De-escalation of five-year adjuvant endocrine therapy in patients with ER-low positive breast cancer: Propensity-matched analysis from a prospectively maintained cohort
Authors: Keda Yu, Yuwen Cai, Zhiming Shao
Journal: Cancer Research (2022)

Abstract Background The standard 5 years of endocrine therapy has shown additional benefits when compared with short-term 2-3 years of treatment in patients with estrogen receptor (ER)-positive breast cancer; however, whether the long-term treatment is still necessary for ER-low positive (1%-10% by immunohistochemistry) breast cancer is unclear. Methods The prospectively maintained Breast Surgery Database of Fudan University Shanghai Cancer Center was used for this propensity-matched analysis. The primary endpoint was disease-free survival (DFS). Multivariate Cox regression and propensity score matching methods were performed to minimize bias. Hazard ratio (HR) with 95% confidence interval (CI) was calculated. All statistics were 2-sided. Results From 2012 to 2017, there were 22768 consecutive women with pathologically confirmed early-stage breast cancer and 1013 (4.45%) were identified as ER-low positive. Among them, 634 cases met the inclusion criteria and were divided into three groups: received no endocrine therapy (n=89); received 2-3 years of endocrine therapy (n=185); and received approximately 5 years of endocrine therapy (n=360). At a median follow-up of 65 months, there was no significant difference in DFS between patients who received 2-3 years and 5 years of endocrine therapy (HR, 0.82; 95% CI: 0.51-1.33; P=0.43). In the multivariate Cox regression analysis of the propensity score-matched samples, the DFS was not significantly better for patients who received 5 years of endocrine therapy than those receiving 2-3 years of treatment (HR, 0.74; 95% CI: 0.41-1.31; P=0.30). Conclusion Short-term 2-3 years of endocrine therapy might be an alternative for ER-low positive breast cancer instead of standard 5 years. Citation Format: Keda Yu, Yuwen Cai, Zhiming Shao. De-escalation of five-year adjuvant endocrine therapy in patients with ER-low positive breast cancer: Propensity-matched analysis from a prospectively maintained cohort [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-13-07.
HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
Authors: Alejandra Gonzalez-Duarte, David Adams, Ivailo Tournev, Mark Taylor, Teresa Coelho, Violaine Plante-Bordeneuve, John Berk, Julian David Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Chongshu Chen, Prajakta Badri, Seth Arum, John Vest, Michael Polydefkis
Journal: Journal of the American College of Cardiology (2022)
HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies
Authors: Alexa Wilden, Aishwarya Sannareddy, Hetal Patel, Shraddha Kansagra, Gurbakhash Kaur, Praveen Ramakrishnan, Prapti Patel, Ansh Mehta, Ankit Kansagra
Journal: Journal of the National Comprehensive Cancer Network (2022)
Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study
Authors: Jianhong Zhu, Zhichao He, Dan Liang, Xiaoxia Yu, Kaifeng Qiu, Junyan Wu
Journal: Thorax (2022)

We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95% CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%).
UTILITY OF CHA2DS2-VASC SCORE AS A PREDICTOR OF READMISSION AND RESOURCE UTILIZATION IN CORONARY ARTERY BYPASS GRAFTING PATIENTS WITHOUT ATRIAL FIBRILLATION
Authors: Raheel Ahmed, Hiroyuki Sawatari, Saurabh Deshpande, Hassan Khan, Providencia Rui, Deepak Padmanabhan, Virend K. Somers, Anwar Chahal, Mohammed Khanji
Journal: Journal of the American College of Cardiology (2022)
FRACTURE OF BIOPROSTHETIC SURGICAL VALVES: INSIGHTS FROM BENCH TESTING OF 15 SURGICAL VALVES WITH COMPUTED TOMOGRAPHY ANGIOGRAPHY EVALUATION
Authors: Santiago Garcia, Go Hashimoto, Robert Steffen, Muhammad Hammadah, Joao L. Cavalcante, Hirotomo Sato, Vinayak Nilkanth Bapat
Journal: Journal of the American College of Cardiology (2022)
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
Authors: David H. M. Steffin, Ibrahim N. Muhsen, LaQuisa C. Hill, Carlos A. Ramos, Nabil Ahmed, Meenakshi Hegde, Tao Wang, Mengfen Wu, Stephen Gottschalk, Sarah B. Whittle, Premal D. Lulla, Maksim Mamonkin, Bilal Omer, Rayne H. Rouce, Andras Heczey, Leonid S. Metelitsa, Bambi J. Grilley, Catherine Robertson, Virginia Torrano, Natalia Lapteva, Adrian P. Gee, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop
Journal: Blood (2022)

Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials for solid tumors. Although the short-term complications of IE cells are well described, there is limited literature summarizing long-term follow-up, including subsequent malignancies. We retrospectively reviewed data from 340 patients treated across 27 investigator-initiated pediatric and adult clinical trials at our center. All patients received IE cells genetically modified with γ-retroviral vectors to treat relapsed and/or refractory hematologic or solid malignancies. In a cumulative 1027 years of long-term follow-up, 13 patients (3.8%) developed another cancer with a total of 16 events (4 hematologic malignancies and 12 solid tumors). The 5-year cumulative incidence of a first subsequent malignancy in the recipients of genetically modified IE cells was 3.6% (95% confidence interval, 1.8% to 6.4%). For 11 of the 16 subsequent tumors, biopsies were available, and no sample was transgene positive by polymerase chain reaction. Replication-competent retrovirus testing of peripheral blood mononuclear cells was negative in the 13 patients with subsequent malignancies tested. Rates of subsequent malignancy were low and comparable to standard chemotherapy. These results suggest that the administration of IE cells genetically modified with γ retroviral vectors does not increase the risk for subsequent malignancy.
SYSTEMIC RV FAILURE WITH SEPTAL BOWING AS A CAUSE OF SAM IN D-TRANSPOSITION OF THE GREAT ARTERIES
Authors: Ali J. Noory, Gursharan Singh Samra, Sunita Mahabir, Sharana Hegde, Kirtivardhan Vashistha, Kartikeya Kashyap, Vinh Q. Nguyen
Journal: Journal of the American College of Cardiology (2022)
Abstract P5-08-07: The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models
Authors: Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner
Journal: Cancer Research (2022)

Abstract The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) oncogene is overexpressed in approximately 25% of breast cancer tumors and is associated with a high rate of brain metastasis. Patients with brain metastases have a poor prognosis and limited treatment options available. Since about half of HER2+ tumors are also hormone receptor positive, and cross talk has been shown to occur between these two signaling pathways, it is plausible that these tumors could benefit from the addition of hormonal therapy on top of HER2 inhibition. OP-1250 is a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), and has been shown to effectively inhibit estrogen receptor positive (ER+) breast cancer growth in both cell-based assays and xenograft studies. OP-1250 has favorable pharmacokinetic properties and demonstrated brain penetrance in non-clinical models. While extensively characterized in ER+/HER2- breast cancer models, OP-1250 had not previously been tested in a HER2+ context. Here we report OP-1250 inhibited estrogen receptor-driven proliferation and effectively degraded the estrogen receptor in multiple ER+/HER2+ cell lines. OP-1250 combined effectively with HER2 inhibitors tucatinib and trastuzumab, demonstrating that inhibition of both HER2 and estrogen receptor signaling was more effective in inhibiting breast cancer cell proliferation than inhibiting either pathway alone. The addition of OP-1250 to a HER2 inhibitor also resulted in greater tumor shrinkage in multiple ER+/HER2+ xenograft models. Our data suggests a potential clinical benefit in the addition of OP-1250 on top of HER2 inhibition for the treatment of ER+/HER2+ breast cancer and provides strong rationale for a clinical study evaluating the combination of OP-1250 and HER2 targeted agents, which is planned for 2022. Citation Format: Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner. The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-08-07.
TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH MORBID OBESITY. A MULTICENTRE PROPENSITY SCORE MATCHED ANALYSIS
Authors: Angela McInerney, Josep Rodés-Cabau, Gabriela Veiga, Diego Lopez-Otero, Erika Muñoz Garcia, Francisco Campelo, Juan Oteo, Jose David Tafur Soto, Amat-Santos Ignacio, Manuel Carnero, Alejandro Travieso Gonzalez, Siamak Mohammadi, Marco Barbanti, Asim N. Cheema, Stefan Toggweiler, Francesco Saia, Maciej Dabrowski, Vicente Serra, Alberto Forteza, Gabriela Tirado-Conte, Nieves Gonzalo, Javier Cobiella, Javier Escaned, Luis Nombela
Journal: Journal of the American College of Cardiology (2022)
ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
Authors: Daisuke Kotani, Yoshiaki Nakamura, Takao Fujisawa, Hideaki Bando, Naoya Sakamoto, Amber L Johns, Keunchil Park, Raffaella Casolino, Takayuki Yoshino, Andrew V Biankin, Andrew V Biankin, Lincoln D Stein, Keunchil Park, Rita T Lawlor, Amber L Johns, Jan O Korbel, Nik Zeps, Mark A Rubin, Marco A Marra, Olivier Elemento, Steven Gallinger, David Tuveson, Lorenz Trumper, Raphael Koch, Aldo Scarpa, Paul Brennan, Christian Pilarsky, Sergey Nikolaev, Sun-Soo Yoon, Eun Sook Lee, Tatsuhiro Shibata, Xiaojian Wu, Jianmin Wu, Qimin Zhan, Wai Poon, Takayuki Yoshino, Khawla S. Al-Kuraya, Rosalind Eeles, Rebecca Fitzgerald, Carlos Caldas, Jean Abraham, David K Chang
Journal: The Lancet Oncology (2022)